Zomedica Corp. · OTC:ZOMDF
Zomedica — Lytham Partners Investor Select Conference 2024
20 slides from Zomedica's conference presentation, Feb 1, 2024
Slide 1: Larry Heaton, Chief Executive Officer
Larry Heaton Chief Executive Officer
Slide 2: Forward Looking Statements
Forward Looking Statements These materials have been prepared for informational purposes only in relation to Zomedica and are not, under any circumstances, to be construed as an offering of any securities for sale directly or indirectly in any province or territory of Canada, in the United States or
Slide 3: Investment Highlights
Investment Highlights Attractive Industry: Humanization of pets driving recession resistant market growth. Differentiated Solutions: Innovative technology to improve care, practice workflow & customer economics Experienced Management Team: Start-up mentality focused on executing plan to profitabilit
Slide 4: Visionary leadership with extensive experience building early-stage companies
Visionary leadership with extensive experience building and developing early-stage companies in animal and human health sectors Larry Heaton Peter Donato Tony Blair Karen DeHaan-Fullerton J.D., Chief Executive Officer Chief Financial Officer Chief Operations General Counsel & Corporate Officer Secre
Slide 5: Zomedica Market Opportunity
Zomedica Market Opportunity $100 Billion 23 Million 95% Market 6 Months – 2 Years <6 Months The Global Veterinary Service 95% of pet % of U.S. Dog Owning Households w/ One or Market Valued owners Strongly More Dogs Under Two Years Old (X) ~$100 Billion in More than Agree or Agree 2020 23 million hou
Slide 6: Challenges our Customers face
Challenges our Customers face- “It’s Never Been Harder To Practice Veterinary Medicine” Labor, both DVM and staff are a critical issue causing While pharmacy revenue remains important Veterinarians to work more than ever. Vet practices are losing out to online retail on critical chronic refills and
Slide 7: Zomedica Mission & Vision
Zomedica Mission & Vision PulseVet® Zomedica is bringing innovative Shock Wave System diagnostic and therapeutic technology to Veterinarians to Assisi LOOP ® improve the quality of care for the pet, the satisfaction of the pet parent, and the workflow, cash flow and profitability of the practice. TR
Slide 8: Five Pillars
Five Pillars Providing Continuous Improvements
Slide 9: Our Portfolio is Well-Positioned to Fill those Critical Needs
Our Portfolio is Well-Positioned to Fill those Critical Needs Therapeutic Systems Diagnostic & Monitoring Devices Proven, effective, sedation- The only all-in-one fully free healing leveraging automated digital microscope high-energy sound wave that prepares and digitizes technology utilized by hema
Slide 10: Zomedica's Significant Serviceable Market Opportunity
Zomedica’s Significant Serviceable Market Opportunity U.S. Customer Base U.S. Total Annual Serviceable Market Opportunity 4,450 Recurring Revenue Capital Revenue Equine or Mixed $1.3 B TRUVIEW Practices $1.0 B $775 M PulseVet TRUFORMA Recurring Annual Per Unit Capital Revenue Range $210 M Revenue Ra
Slide 11: Zomedica Revenue Up ~32% vs. 2022
Zomedica Revenue Up ~32%* vs. 2022 All Figures In Thousands Total Revenue(1) International Qorvo and VetGuardian Revenue: 2021: $4.1M Agreements • 15-20% from PulseVet® +* and Assisi® 2022: $18.9M 2023: $25M+* PulseVet, Revo, and Assisi Acquisitions Planned for 2024 Int’l 2024 Guidance: Launch: $31-
Slide 12: Reference Lab Accuracy at the Point of Care with TRUFORMA
Reference Lab Accuracy at the Point of Care with TRUFORMA Diagnostic Platform Disposable cartridge preloaded with reagents Timely and accurate results Minimizes sample prep & simplifies workflow Supports practitioner’s ability to diagnose with confidence Product Overview Reference Lab Compact instru
Slide 13: TRUFORMA Assay Development
TRUFORMA Assay Development On the Market In Development Opportunities Expanding into high-value Becoming a broad-based Currently Available Point-of Care solution Point-of-Care solution Endocrine & Thyroid Disease • Canine TSH (cTSH) • Feline TSH (fTSH)1 Reproduction • Canine Total T4 (TT4) • Canine
Slide 14: Digital Cytology Platform & Pathology Services
Digital Cytology Platform & Pathology Product Overview Services Perfect smear, stain, With TRUprepTM Fully Automated Slide Prep scan, and slide every time • Innovative digital imaging system with • Improves workflow in the clinic LiquiView liquid lens optics provide best- in-class visualization • Re
Slide 15: Wireless Remote Monitoring System
Wireless Remote Monitoring System Improved care for pet patients Enhanced workflow and new revenue stream for Product Overview practice The technology: Convenient. • Continuous waveform doppler radar detects Easy to Use. pulse and respiration Anytime. Anywhere. • Video camera and LIDAR sensors detec
Slide 16: The Global Leader in Shock Wave Technology
The Global Leader in Shock Wave Technology The PulseVet® shock wave technology has been clinically Tech / IP proven to enhance the quality and speed of healing in • 14 Published clinical studies, including randomized control trials various musculoskeletal indications, from ligament and Product Overv
Slide 17: Assisi Product Line Complements PulseVet
Assisi Product Line Complements PulseVet with home supplemental treatment Assisi Loop® with home&supplemental Assisi Loop Lounge® treatment DentaLoop® device indicated for gum disease and pain from extractions Sold for pain and inflammation from OA, and wound healing Calmer Canine® system for separa
Slide 18: Our Objectives – Zomedica's Five Pillars for Ongoing M&A
Our Objectives – Zomedica’s Five Pillars for Ongoing M&A 1 Improving the quality of care for the pet • Reference lab accuracy diagnostics at point of care • Cloud based integrated patient monitoring • Clinically validated treatments that work; Benefits are observable Improving the satisfaction of th
Slide 19: Why Invest In Zomedica?
Why Invest In Zomedica? New Product Launches Veteran management team - Assisi 3Q22 Track record, leadership & leading revenue growth and - VetGuardian 1Q23 capital to continue acquisitions - TRUVIEW 2Q23 driving to profitability in large, - TRUFORMA 2023-2024 of complementary products to growing, re
Slide 20: investors@zomedica.com
investors@zomedica.com © 2024 Zomedica Inc.
Zomedica — Lytham Partners Investor Select Conference 2024 on 6ix